Trial Parameters
Brief Summary
A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of genotype-guided targeted agents plus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP-X) versus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with diffuse large B-cell lymphoma
Eligibility Criteria
Inclusion Criteria: * Histologically-confirmed diffuse large B-cell lymphoma (without central nervous system involvement) * Availability of archival or freshly collected tumor tissue before study enrolment * International Prognostic Index (IPI) score of 2-5 or 1 with bulky disease * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2 * Life expectancy greater than or equal to (\>/=) 6 months * The patient or his or her legal representative must provide written informed consent prior to any special examination or procedure for the research Exclusion Criteria: * Previous chemotherapy. * Previous stem cell transplantation. * History of malignancies except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix * Uncontrolled cardio- and cerebro-vascular disease, blood clotting disorders, connective tissue diseases, serious infectious diseases and other diseases * Patients with central nervous system (CNS) lymphoma * Primary mediastin